Not Tripping over TRIPS: An Analysis of Necessity and Legality of the COVID-19 TRIPS Waiver Proposal
Creators
- 1. 4th Year BA. LLB Candidate, O.P. Jindal Global University, Jindal Global Law School, Sonipat, India.
- 2. 1st Year BA. LLB Candidate, O.P. Jindal Global University, Jindal Global Law School, Sonipat, India.
Contributors
- 1. Publisher
Description
The availability of vaccinations against COVID-19 provides hope for containing the epidemic, which has already claimed over 2.84 million lives. However, inoculating millions of individuals worldwide would need large vaccine manufacturing followed by fair distribution. A barrier to vaccine development and dissemination is the developers' intellectual property rights. India and South Africa have jointly sought to the World Trade Organization that certain TRIPS rules of COVID-19 vaccines, medicines, and treatments be waived. This piece argues for such a waiver, highlighting the unique circumstances that exist. It believes that TRIPS's flexibilities are inadequate to cope with the present epidemic, particularly for nations without pharmaceutical manufacturing competence.
Files
E66750110522.pdf
Files
(282.3 kB)
Name | Size | Download all |
---|---|---|
md5:6a2f61cdc792a0551ecef97d92854094
|
282.3 kB | Preview Download |
Additional details
Related works
- Is cited by
- Journal article: 2277-3878 (ISSN)
Subjects
- ISSN
- 2277-3878
- Retrieval Number
- 100.1/ijrte.E66750110522